PCSK9 and familial hyperaldosteronism: The genomic examination of FH patients at risk for PCSK9/LDLR and APOB polymorphisms has become necessary to ameliorate clinical diagnosis and management by considering the use of PCSK9 inhibitors in their therapeutic care plan.